Imprimis Pharma (IMMY) Reports Q4 Loss of $0.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results and Provides Business Update
March 12, 2015 4:05 PM EDTSAN DIEGO, March 12, 2015 /PRNewswire/ --Â Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014, and will provide an update on recent business developments on a conference call this afternoon.
Key 2014 and Recent Developments:
Launched our ophthalmology business in April 2014 with our Go Dropless educational campaign and flagship Dropless Therapy formulations for... More